Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Tycho Peterson | Jefferies | 9 questions · 56% challenging |
| Vijay Kumar | Evercore ISI | 8 questions · 13% challenging |
| Kyle Mikson | Canaccord Genuity | 8 questions · 0% challenging |
| Subha Nambi | Guggenheim | 8 questions · 0% challenging |
| Puneet Souda | Leerink Partners | 7 questions · 0% challenging |
| Doug Schenkel | UBS | 7 questions · 14% challenging |
| David Westenberg | Piper Sandler | 6 questions · 0% challenging |
| Dan Arias | Stifel | 5 questions · 20% challenging |
| Dan Brennan | TD Cowen | 5 questions · 0% challenging |
| Jack Meehan | Operon Research | 5 questions · 0% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Jefferies | 1 analyst | 9 questions · 56% challenging |
| UBS | 2 analysts | 9 questions · 11% challenging |
| Canaccord Genuity | 1 analyst | 8 questions · 0% challenging |
| Evercore ISI | 1 analyst | 8 questions · 13% challenging |
| Guggenheim | 1 analyst | 8 questions · 0% challenging |
| Leerink Partners | 1 analyst | 7 questions · 0% challenging |
| JPMorgan | 2 analysts | 6 questions · 0% challenging |
| Piper Sandler | 1 analyst | 6 questions · 0% challenging |
No 8-K events recorded for this window.
Illumina delivered its fastest revenue growth since CEO Jacob Thaysen joined, with second-quarter 2026 revenue of $1.16 billion up 9.5% year-over-year (6.5% organic; Rest of World organic +8.1%) and non-GAAP EPS of $1.31 up approximately 10% (13% ex-acquisitions). Clinical remained the primary driver, growing 15% ex-China with the U.S.-Canada region above 20%, while research and applied consumables declined 7% but improved sequentially with tentative late-quarter signs of recovery. NovaSeq X demand stayed elevated with more than 95 placements, and non-GAAP operating margin of 22.5% (about 23% excluding a deferred-comp item) came in above guidance despite higher memory and freight costs. Management raised full-year Rest-of-World organic growth guidance to greater than 5% (from 2% to 4%), reported revenue to $4.60 billion to $4.64 billion, and non-GAAP EPS to $5.30 to $5.40, while advancing multiomics via the StrataMap spatial launch, SomaLogic integration, and early Billion Cell Atlas revenue.
Demand | Revenue Growth | Product Launch | Guidance Reliability | Competitive Dynamics | Margin | Geographic Expansion | Cost Pressure | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 3 | 1 | 2 | 1 | 1 | 2 | 2 | 1 |
| 2025Q1 | 4 | 1 | 1 | 3 | 2 | 1 | ||
| 2025Q2 | 4 | 3 | 2 | 5 | 2 | 1 | ||
| 2025Q3 | 4 | 3 | 4 | 4 | 1 | 2 | 1 | 1 |
| 2025Q4 | 5 | 3 | 4 | 2 | 2 | 1 | 1 | |
| 2026Q1 | 4 | 5 | 7 | 3 | 4 | 2 | 2 | |
| 2026Q2 | 4 | 6 | 2 | 3 | 1 | 1 | 2 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | '26Q2 | |
|---|---|---|---|---|---|---|---|
| Demand | 3 | 4 | 4 | 4 | 5 | 4 | 4 |
| Revenue Growth | 1 | 1 | 3 | 3 | 3 | 5 | 6 |
| Product Launch | 2 | 2 | 4 | 4 | 7 | 2 | |
| Guidance Reliability | 1 | 1 | 5 | 4 | 2 | 3 | 3 |
| Competitive Dynamics | 1 | 3 | 2 | 1 | 2 | 4 | 1 |
| Margin | 2 | 2 | 1 | 2 | 1 | ||
| Geographic Expansion | 2 | 2 | 1 | 1 | 1 | ||
| Cost Pressure | 1 | 1 | 1 | 2 | 2 |
Calendar quarter Q2 2026Earnings call Jul 30, 2026
FY2026 Q2 in brief
Illumina delivered its fastest revenue growth since CEO Jacob Thaysen joined, with second-quarter 2026 revenue of $1.16 billion up 9.5% year-over-year (6.5% organic; Rest of World organic +8.1%) and non-GAAP EPS of $1.31 up approximately 10% (13%…
Newest scored quarter FY2026 Q3 is part of Pro · see what Pro adds →
Sources. Tellvest earnings-call sentiment score for Illumina, Inc. (ILMN), FY2026 Q2: 8/10. Scores: Illumina, Inc.’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: ILMN daily prices (open, high, low, close) with a 50-day moving average; lines mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $1.10B | -1.6% | $1.17 | n/m | 65.9% | 15.9% | 16.9% | $335M |
| FY2025 Q1 | $1.04B | -3.3% | $0.82 | n/m | 65.6% | 15.8% | 12.6% | $208M |
| FY2025 Q2 | $1.06B | -4.8% | $1.49 | n/m | 65.6% | 20.2% | 22.2% | $204M |
| FY2025 Q3 | $1.08B | +0.4% | $0.98 | -77.8% | 67.6% | 20.9% | 13.8% | $253M |
| FY2025 Q4 | $1.16B | +5.0% | $2.16 | +84.6% | 65.5% | 17.3% | 28.8% | $266M |
| FY2026 Q1 | $1.09B | +4.8% | $0.87 | +6.1% | 66.1% | 19.2% | 12.3% | $251M |
| FY2026 Q2Selected | $1.16B | +9.4% | $1.35 | -9.4% | 66.4% | 21.1% | 17.9% | $161M |
| FY2026 Q3 | $1.13B | +4.2% | $1.43 | +45.9% | 73.5% | 27.0% | 19.5% | $379M |
FY2024 Q4: Prior-year quarter was a loss (-$1.11 EPS), so a percent change isn't meaningful.
GAAP revenue YoY +9.65% → base 7. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
FY2025 Q1: Prior-year quarter was a loss (-$0.79 EPS), so a percent change isn't meaningful.
FY2025 Q2: Prior-year quarter was a loss (-$12.48 EPS), so a percent change isn't meaningful.
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
Mentions of other companies on ILMN's FY2026 Q2 call, and mentions of ILMN on other companies' calls covering the same calendar quarter (Q2 2026). Each company's own fiscal quarter is shown next to its name. Extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“included SomaLogic revenue, which continues to track towards the high end of our deal expectations.”
Acquired SomaLogic revenue (in microarrays and other) is tracking toward the high end of Illumina’s deal expectations, indicating a successful integration.
| Company | Score | Trend | Rev YoY | Headline |
|---|---|---|---|---|
| ILMNIllumina, Inc. | 8 | +9.7% | Illumina delivered its fastest revenue growth since CEO Jacob Thaysen joined, with second-quarter 2026 revenue of $1.16 billion up 9.5% year-over-year (6.5% organic; Rest of World organic +8.1%) and non-GAAP EPS of $1.31 up approximately 10% (13% ex-acquisitions) | |
| AAgilent Technologies | 8 | +10.0% | Agilent delivered a strong Q2 with $1.83 billion in revenue growing 6.3% core, beating guidance by 80 basis points on broad-based instrument strength including low double digit LC, LCMS, and GC growth | |
| CRLCharles River Laboratories | 4 | -2.7% | Charles River returned to organic revenue growth for the first time since the third quarter of 2023, with total-company organic revenue up 0.1% (reported revenue lower on completed divestitures) and non-GAAP EPS of $3.02 topping the prior outlook | |
| DGXQuest Diagnostics | 8 | +10.2% | Quest Diagnostics delivered a strong second quarter, growing consolidated revenue 10.2% (10% organic) on a 13.1% increase in requisition volume across its physician, hospital and consumer channels, aided by the Corewell Health and Fresenius Medical Care collaborations | |
| DHRDanaher Corporation | 6 | +5.5% | Danaher delivered a better-than-expected second quarter, with sales of $6.3 billion and core revenue up 3%; excluding respiratory testing, core growth was 4.5%, a 150 basis point acceleration from the first quarter | |
| IDXXIdexx Laboratories | 8 | +9.7% | IDEXX grew revenue about 10% as reported and 9% organically, delivering reported EPS of $4.27 (up 18% as reported and 15% on a comparable basis) as CAG Diagnostics recurring revenue rose 10.3% organically and comparable operating margin expanded 110 basis points | |
| IQVIQVIA | 8 | +8.7% | IQVIA's second quarter revenue of $4.368 billion grew 8.7% on a reported basis and 8.5% at constant currency, with organic growth accelerating to 6%, three times the rate delivered a year ago | |
| LHLabCorp | 8 | +5.8% | Enterprise revenue grew 5.8% to $3.7 billion with adjusted EPS of $4.99, up 14.9%, as adjusted operating margin expanded 70 basis points to 15.8% in what management called the fifth consecutive quarter of margin expansion across both segments | |
| MTDMettler Toledo | 7 | +4.5% | Mettler-Toledo delivered a strong beat-and-raise quarter, with sales of $1 billion up 7% in U.S | |
| RVTYRevvity | 6 | +1.3% | Revvity delivered a beat-and-raise second quarter, with pro forma organic growth of 3% and pro forma adjusted EPS of $1.41 both above the high end of guidance, though about half the EPS upside came from $16 million of one-time tariff refunds and much of the rest from tax timing | |
| TMOThermo Fisher Scientific | 8 | +10.5% | Thermo Fisher delivered a broad-based beat, with reported revenue up 10% to $11.99 billion (5% organic) and GAAP EPS of $4.68, up 9%; adjusted EPS rose 13% to $6.03 | |
| WATWaters Corporation | 7 | +113.3% | Waters delivered total revenue of $1.645 billion in its first full quarter owning the acquired Biosciences and Diagnostic Solutions businesses, composed of $828 million organic (+7% as reported, +9% constant currency, above the high end of guidance) and $817 million from the acquired units, which grew 4% as reported and beat guidance by $15 million |
Illumina delivered its fastest revenue growth since CEO Jacob Thaysen joined, with second-quarter 2026 revenue of $1.16 billion up 9.5% year-over-year (6.5% organic; Rest of World organic +8.1%) and non-GAAP EPS of $1.31 up approximately 10% (13% ex-acquisitions)
Agilent delivered a strong Q2 with $1.83 billion in revenue growing 6.3% core, beating guidance by 80 basis points on broad-based instrument strength including low double digit LC, LCMS, and GC growth
Charles River returned to organic revenue growth for the first time since the third quarter of 2023, with total-company organic revenue up 0.1% (reported revenue lower on completed divestitures) and non-GAAP EPS of $3.02 topping the prior outlook
| Company | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
| ILMN | 2 | 6 | 6 | 8 | 8 | 8 |
| A | 5 | 6 | 8 | 8 | 6 | 8 |
| CRL | 6 | 8 | 7 | 4 | 4 | 4 |
| DGX | 7 | 8 | 8 | 7 | 9 | 8 |
| DHR | 4 | 7 | 7 | 7 | 7 | 6 |
| IDXX | 6 | 8 | 8 | 9 | 8 | 8 |
| IQV | 5 | 6 | 6 | 8 | 7 | 8 |
| LH | 7 | 9 | 9 | 8 | 8 | 8 |
| MTD | 5 | 6 | 7 | 7 | 7 | 7 |
| RVTY | 5 | 5 | 5 | 6 | 5 | 6 |
| TMO | 3 | 6 | 7 | 7 | 7 | 8 |
| WAT | 8 | 7 | 9 | 7 | 9 | 7 |
Quest Diagnostics delivered a strong second quarter, growing consolidated revenue 10.2% (10% organic) on a 13.1% increase in requisition volume across its physician, hospital and consumer channels, aided by the Corewell Health and Fresenius Medical Care collaborations
Danaher delivered a better-than-expected second quarter, with sales of $6.3 billion and core revenue up 3%; excluding respiratory testing, core growth was 4.5%, a 150 basis point acceleration from the first quarter
IDEXX grew revenue about 10% as reported and 9% organically, delivering reported EPS of $4.27 (up 18% as reported and 15% on a comparable basis) as CAG Diagnostics recurring revenue rose 10.3% organically and comparable operating margin expanded 110 basis points
IQVIA's second quarter revenue of $4.368 billion grew 8.7% on a reported basis and 8.5% at constant currency, with organic growth accelerating to 6%, three times the rate delivered a year ago
Enterprise revenue grew 5.8% to $3.7 billion with adjusted EPS of $4.99, up 14.9%, as adjusted operating margin expanded 70 basis points to 15.8% in what management called the fifth consecutive quarter of margin expansion across both segments
Mettler-Toledo delivered a strong beat-and-raise quarter, with sales of $1 billion up 7% in U.S
Revvity delivered a beat-and-raise second quarter, with pro forma organic growth of 3% and pro forma adjusted EPS of $1.41 both above the high end of guidance, though about half the EPS upside came from $16 million of one-time tariff refunds and much of the rest from tax timing
Thermo Fisher delivered a broad-based beat, with reported revenue up 10% to $11.99 billion (5% organic) and GAAP EPS of $4.68, up 9%; adjusted EPS rose 13% to $6.03
Waters delivered total revenue of $1.645 billion in its first full quarter owning the acquired Biosciences and Diagnostic Solutions businesses, composed of $828 million organic (+7% as reported, +9% constant currency, above the high end of guidance) and $817 million from the acquired units, which grew 4% as reported and beat guidance by $15 million